Kevin Hakimi on the Rationale of the PADRES Trial in RCC
Kevin Hakimi, discusses the rationale for the phase 2 PADRES trial in clear cell renal cell carcinoma.
Immunotherapy Monotherapy Leads to Antigen Loss and Treatment Resistance in Myeloma
PVd Extends OS and PFS in Relapsed/Refractory Multiple Myeloma
At Multiple Dose Levels, Mezigdomide Elicits Responses in Combination With Bortezomib or Carfilzomib in R/R Myeloma
Durcabtagene Autoleucel Demonstrates Rapid Proliferation and Persistence in Relapsed/Refractory Myeloma
2 Clarke Drive Cranbury, NJ 08512